Platelets in radiation-induced immune dysregulation

辐射引起的免疫失调中的血小板

基本信息

  • 批准号:
    10670943
  • 负责人:
  • 金额:
    $ 64.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-07-25 至 2027-05-31
  • 项目状态:
    未结题

项目摘要

RESEARCH SUMMARY In a large-scale nuclear event, many people could be exposed to high doses of ionizing radiation (IR). This can have long-term adverse effects on immune function, putting victims at risk for immune disorders and contributing to the dysfunction of organs that depend on a functional immune system. Currently no FDA-approved drugs are available to mitigate immune dysregulation in radiation victims. The overall objectives of this project are to understand how platelets contribute to immune dysregulation after exposure to IR and to test platelet-centric countermeasures to mitigate IR-induced immune dysregulation and organ damage (specifically in the intestine and heart). Platelets can regulate immune function by binding directly to immune cells or by delivering submicron platelet-derived microparticles (PMPs) to the cells. In every healthy individual, platelets form platelet–leukocyte aggregates and generate PMPs in the circulation under normal conditions, but these activities increase under pathological conditions. Various platelet receptors interact with their specific counter receptors on leukocytes, specifically polymorphonuclear neutrophils (PMNs) and monocytes—2 crucial members of the innate immune system that can modify the adaptive immune response—to form platelet–leukocyte aggregates. Central to this interaction is platelet glycoprotein Ibα (GPIbα) binding to leukocyte Mac-1, resulting in activation of both platelets and leukocytes. PMPs can activate PMNs and monocytes by delivering cytokines, growth factors, and RNA. Notably, proteolytic cleavage of platelet GPVI is an essential step for PMP generation. Our preliminary data show that mice with dysfunctional GPIbα (cannot bind Mac-1) exhibit increased inflammation, intestinal injury, PMP generation, and lethality following a single dose of 8.5 Gy total-body irradiation (TBI) compared to wild-type mice. Moreover, we showed that mice with dysfunctional GPIbα are more prone to inflammation following polymicrobial sepsis, which can occur after IR exposure. Finally, GPVI-KO mice generate fewer PMPs and exhibit reduced plasma pro-inflammatory cytokine levels compared to mice with dysfunctional GPIbα after 8.5 Gy TBI. We hypothesize that lack of GPIbα–Mac-1 interaction and enhanced PMP generation contribute to IR-induced immune dysregulation and predict that administering exogenous GPIbα or limiting PMP generation will mitigate IR-induced immune dysregulation and organ damage. The studies outlined in this proposal will: 1) Determine whether selective blocking of GPIbα binding to Mac-1 exacerbates, while exogenous GPIbα administration mitigates, TBI-induced immune dysregulation and 2) Evaluate whether limiting PMP generation by inhibiting GPVI mitigates TBI-induced immune dysregulation. Our studies will provide insight into the previously unexplored role of platelet–leukocyte interaction and PMP generation in modulating IR-induced immune dysregulation. Most importantly, the findings will help to develop novel radiation mitigators.
研究综述 在大规模核事件中,许多人可能暴露在高剂量的电离辐射(IR)中。这可以 对免疫功能有长期的不利影响,使受害者面临免疫紊乱的风险,并导致 依赖于功能免疫系统的器官功能障碍。目前还没有FDA批准的药物 可用于缓解辐射受害者的免疫失调。该项目的总体目标是 了解暴露于IR后,血小板如何导致免疫失调,并检测以血小板为中心的 减轻IR诱导的免疫失调和器官损伤(特别是肠道损伤)的对策 和心)。血小板可以通过直接与免疫细胞结合或通过运送亚微米颗粒来调节免疫功能。 血小板源微粒(PMPs)进入细胞。在每个健康的个体中,血小板形成血小板-白细胞 在正常情况下,在循环中聚集和产生PMP,但这些活动在 病理情况。不同的血小板受体与其在白细胞上的特异性对应物受体相互作用, 特别是中性粒细胞(PMN)和单核细胞--天然免疫的两个重要成员 可以改变适应性免疫反应的系统--形成血小板-白细胞聚集体。这是关键所在 相互作用是血小板膜糖蛋白Ibα(GPIBα)与白细胞Mac-1结合,导致两个血小板的激活 和白细胞。PMPs可以通过递送细胞因子、生长因子和RNA来激活PMN和单核细胞。 值得注意的是,蛋白水解性裂解血小板GPVI是产生PMP的关键步骤。我们的初步数据显示 患有功能障碍的GPIBα(不能结合Mac-1)的小鼠表现出更多的炎症,肠道损伤,PMP 与野生型小鼠相比,单次8.5Gy体照射(TBI)后的小鼠死亡率、世代数和致死率都有所下降。 此外,我们发现具有功能障碍的gpibα的小鼠在服用多菌素后更容易发生炎症。 败血症,暴露于红外线后可能发生。最后,GPVI-KO小鼠产生的PMP更少,表现为减少 8.5GyTBI后血浆促炎细胞因子水平与GPIBα功能障碍小鼠的比较。我们 假设缺乏GPIBα-Mac-1相互作用和增强的PMP生成有助于IR的诱导 免疫失调和预测,服用外源性GPIBα或限制PMP产生将缓解 IR引起的免疫失调和器官损伤。本提案中概述的研究将:1)确定 选择性阻断GPIBα与Mac-1的结合是否加剧,同时外源性GPIBα管理 缓解脑损伤诱导的免疫失调,以及2)评估是否通过抑制PMP的产生来限制PMP的产生 GPVI可减轻脑外伤所致的免疫失调。我们的研究将为我们提供对以前 血小板-白细胞相互作用和PMP生成在调节IR诱导免疫中的作用 监管失调。最重要的是,这些发现将有助于开发新型的辐射缓释剂。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Martin J Cannon其他文献

Martin J Cannon的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Martin J Cannon', 18)}}的其他基金

Platelets in radiation-induced immune dysregulation
辐射引起的免疫失调中的血小板
  • 批准号:
    10474901
  • 财政年份:
    2022
  • 资助金额:
    $ 64.91万
  • 项目类别:
Dendritic cell immunotherapy for ovarian cancer
卵巢癌的树突状细胞免疫疗法
  • 批准号:
    6882806
  • 财政年份:
    2005
  • 资助金额:
    $ 64.91万
  • 项目类别:
Novel target antigens for ovarian cancer immunotherapy
卵巢癌免疫治疗的新靶抗原
  • 批准号:
    6933008
  • 财政年份:
    2004
  • 资助金额:
    $ 64.91万
  • 项目类别:
Novel target antigens for ovarian cancer immunotherapy
卵巢癌免疫治疗的新靶抗原
  • 批准号:
    6826415
  • 财政年份:
    2004
  • 资助金额:
    $ 64.91万
  • 项目类别:
Novel target antigens for ovarian cancer immunotherapy
卵巢癌免疫治疗的新靶抗原
  • 批准号:
    7227892
  • 财政年份:
    2004
  • 资助金额:
    $ 64.91万
  • 项目类别:
Novel target antigens for ovarian cancer immunotherapy
卵巢癌免疫治疗的新靶抗原
  • 批准号:
    7103692
  • 财政年份:
    2004
  • 资助金额:
    $ 64.91万
  • 项目类别:
T-CELL IMMUNOTHERAPY OF EBV ASSOCIATED LYMPHOMA
EBV 相关淋巴瘤的 T 细胞免疫治疗
  • 批准号:
    2106106
  • 财政年份:
    1994
  • 资助金额:
    $ 64.91万
  • 项目类别:
T-CELL IMMUNOTHERAPY OF EBV ASSOCIATED LYMPHOMA
EBV 相关淋巴瘤的 T 细胞免疫治疗
  • 批准号:
    2106107
  • 财政年份:
    1994
  • 资助金额:
    $ 64.91万
  • 项目类别:
T-CELL IMMUNOTHERAPY OF EBV ASSOCIATED LYMPHOMA
EBV 相关淋巴瘤的 T 细胞免疫治疗
  • 批准号:
    2376932
  • 财政年份:
    1994
  • 资助金额:
    $ 64.91万
  • 项目类别:
T-CELL IMMUNOTHERAPY OF EBV ASSOCIATED LYMPHOMA
EBV 相关淋巴瘤的 T 细胞免疫治疗
  • 批准号:
    2667981
  • 财政年份:
    1994
  • 资助金额:
    $ 64.91万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 64.91万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.91万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 64.91万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.91万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 64.91万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 64.91万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.91万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 64.91万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 64.91万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.91万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了